{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:36:17Z","timestamp":1768005377512,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,9]],"date-time":"2011-10-09T00:00:00Z","timestamp":1318118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00262-011-1109-0","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T14:23:15Z","timestamp":1318083795000},"page":"523-533","source":"Crossref","is-referenced-by-count":5,"title":["Tipifarnib-mediated suppression of T-bet-dependent signaling pathways"],"prefix":"10.1007","volume":"61","author":[{"given":"Fanqi","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro V.","family":"Villagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JianXiang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Painter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirby","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Blaskovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie Y.","family":"Djeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pearlie","family":"Epling-Burnette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,9]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.V81.9.2363.2363","volume":"81","author":"R Nash","year":"1993","unstructured":"Nash R, McSweeney P, Zambello R, Semenzato G, Loughran TP Jr (1993) Clonal studies of CD3-lymphoproliferative disease of granular lymphocytes. Blood 81:2363\u20132368","journal-title":"Blood"},{"key":"1109_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V82.1.1.bloodjournal8211","volume":"82","author":"TP Loughran Jr","year":"1993","unstructured":"Loughran TP Jr (1993) Clonal diseases of large granular lymphocytes. Blood 82:1\u201314","journal-title":"Blood"},{"key":"1109_CR3","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1182\/blood-2008-02-136382","volume":"112","author":"PK Epling-Burnette","year":"2008","unstructured":"Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J et al (2008) Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 112:4694\u20134698","journal-title":"Blood"},{"key":"1109_CR4","doi-asserted-by":"crossref","first-page":"16308","DOI":"10.1073\/pnas.0806447105","volume":"105","author":"R Zhang","year":"2008","unstructured":"Zhang R, Shah MV, Yang J, Nyland SB, Liu X et al (2008) Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 105:16308\u201316313","journal-title":"Proc Natl Acad Sci USA"},{"key":"1109_CR5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG et al (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655\u2013669","journal-title":"Cell"},{"key":"1109_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0167-5699(00)01712-6","volume":"21","author":"J Rengarajan","year":"2000","unstructured":"Rengarajan J, Szabo SJ, Glimcher LH (2000) Transcriptional regulation of Th1\/Th2 polarization. Immunol Today 21:479\u2013483","journal-title":"Immunol Today"},{"key":"1109_CR7","doi-asserted-by":"crossref","first-page":"15818","DOI":"10.1073\/pnas.2636938100","volume":"100","author":"BM Sullivan","year":"2003","unstructured":"Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH (2003) Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci USA 100:15818\u201315823","journal-title":"Proc Natl Acad Sci USA"},{"key":"1109_CR8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrg904","volume":"3","author":"O Avni","year":"2002","unstructured":"Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH et al (2002) T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 3:643\u2013651","journal-title":"Nat Immunol"},{"key":"1109_CR9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1074-7613(00)80642-1","volume":"9","author":"S Agarwal","year":"1998","unstructured":"Agarwal S, Rao A (1998) Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 9:765\u2013775","journal-title":"Immunity"},{"key":"1109_CR10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1067\/mai.2002.121145","volume":"109","author":"M Valapour","year":"2002","unstructured":"Valapour M, Guo J, Schroeder JT, Keen J, Cianferoni A et al (2002) Histone deacetylation inhibits IL4 gene expression in T cells. J Allergy Clin Immunol 109:238\u2013245","journal-title":"J Allergy Clin Immunol"},{"key":"1109_CR11","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1126\/science.1059835","volume":"292","author":"AC Mullen","year":"2001","unstructured":"Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV et al (2001) Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292:1907\u20131910","journal-title":"Science"},{"key":"1109_CR12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ni794","volume":"3","author":"M Afkarian","year":"2002","unstructured":"Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N et al (2002) T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 3:549\u2013557","journal-title":"Nat Immunol"},{"key":"1109_CR13","doi-asserted-by":"crossref","unstructured":"O\u2019Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327:1098\u20131102","DOI":"10.1126\/science.1178334"},{"key":"1109_CR14","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood-2007-08-106005","volume":"110","author":"R Zeiser","year":"2007","unstructured":"Zeiser R, Youssef S, Baker J, Kambham N, Steinman L et al (2007) Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 110:4588\u20134598","journal-title":"Blood"},{"key":"1109_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1084\/jem.20051129","volume":"203","author":"SE Dunn","year":"2006","unstructured":"Dunn SE, Youssef S, Goldstein MJ, Prod\u2019homme T, Weber MS et al (2006) Isoprenoids determine Th1\/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203:401\u2013412","journal-title":"J Exp Med"},{"key":"1109_CR16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL et al (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78\u201384","journal-title":"Nature"},{"key":"1109_CR17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/sj.onc.1201296","volume":"15","author":"EC Lerner","year":"1997","unstructured":"Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD et al (1997) Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283\u20131288","journal-title":"Oncogene"},{"key":"1109_CR18","first-page":"1846","volume":"57","author":"K Miquel","year":"1997","unstructured":"Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD et al (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57:1846\u20131850","journal-title":"Cancer Res"},{"key":"1109_CR19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/13543781003801076","volume":"19","author":"PK Epling-Burnette","year":"2010","unstructured":"Epling-Burnette PK, Loughran TP Jr (2010) Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs 19:689\u2013698","journal-title":"Expert Opin Investig Drugs"},{"key":"1109_CR20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/shem.2002.36925","volume":"39","author":"R Kurzrock","year":"2002","unstructured":"Kurzrock R, Cortes J, Kantarjian H (2002) Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 39:20\u201324","journal-title":"Semin Hematol"},{"key":"1109_CR21","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1021\/bi049723b","volume":"43","author":"TS Reid","year":"2004","unstructured":"Reid TS, Beese LS (2004) Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 43:6877\u20136884","journal-title":"Biochemistry"},{"key":"1109_CR22","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2007-09-112730","volume":"111","author":"M Raponi","year":"2008","unstructured":"Raponi M, Lancet JE, Fan H, Dossey L, Lee G et al (2008) A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111:2589\u20132596","journal-title":"Blood"},{"key":"1109_CR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-4-56","volume":"4","author":"M Raponi","year":"2004","unstructured":"Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D et al (2004) Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4:56","journal-title":"BMC Cancer"},{"key":"1109_CR24","first-page":"491","volume":"2","author":"JE Karp","year":"2008","unstructured":"Karp JE, Lancet JE (2008) Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics 2:491\u2013500","journal-title":"Biologics"},{"key":"1109_CR25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/leu.2008.341","volume":"23","author":"JM Brandwein","year":"2009","unstructured":"Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC et al (2009) A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60\u00a0years and over. Leukemia 23:631\u2013634","journal-title":"Leukemia"},{"key":"1109_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2006.12.001","volume":"21","author":"JL Harousseau","year":"2007","unstructured":"Harousseau JL (2007) Farnesyltransferase inhibitors in hematologic malignancies. Blood Rev 21:173\u2013182","journal-title":"Blood Rev"},{"key":"1109_CR27","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1182\/blood-2006-09-046144","volume":"109","author":"JL Harousseau","year":"2007","unstructured":"Harousseau JL, Lancet JE, Reiffers J, Lowenberg B, Thomas X et al (2007) A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109:5151\u20135156","journal-title":"Blood"},{"key":"1109_CR28","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2005-04-1640","volume":"106","author":"BF Goemans","year":"2005","unstructured":"Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE et al (2005) In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 106:3532\u20133537","journal-title":"Blood"},{"key":"1109_CR29","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/leu.2010.81","volume":"24","author":"C Biagi","year":"2010","unstructured":"Biagi C, Astolfi A, Masetti R, Serravalle S, Franzoni M et al (2010) Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. Leukemia 24:1230\u20131233","journal-title":"Leukemia"},{"key":"1109_CR30","doi-asserted-by":"crossref","unstructured":"Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK et al (2011) Multi-institutional phase II of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood [Epub ahead of print]","DOI":"10.1182\/blood-2011-02-334904"},{"key":"1109_CR31","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood-2006-06-031088","volume":"110","author":"RE Marks","year":"2007","unstructured":"Marks RE, Ho AW, Robbel C, Kuna T, Berk S et al (2007) Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood 110:1982\u20131988","journal-title":"Blood"},{"key":"1109_CR32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2404590","volume":"21","author":"PK Epling-Burnette","year":"2007","unstructured":"Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D et al (2007) Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 21:659\u2013667","journal-title":"Leukemia"},{"key":"1109_CR33","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1038\/sj.onc.1208122","volume":"23","author":"PK Epling-Burnette","year":"2004","unstructured":"Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS et al (2004) ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 23:9220\u20139229","journal-title":"Oncogene"},{"key":"1109_CR34","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2008-07-168245","volume":"113","author":"X Chen","year":"2009","unstructured":"Chen X, Bai F, Sokol L, Zhou J, Ren A et al (2009) A critical role for DAP10 and DAP12 in CD8+ cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 113:3226\u20133234","journal-title":"Blood"},{"key":"1109_CR35","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/leu.2009.14","volume":"23","author":"JX Zou","year":"2009","unstructured":"Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM et al (2009) Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 23:1288\u20131296","journal-title":"Leukemia"},{"key":"1109_CR36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","volume":"10","author":"A Villagra","year":"2009","unstructured":"Villagra A, Cheng F, Wang HW, Suarez I, Glozak M et al (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10:92\u2013100","journal-title":"Nat Immunol"},{"key":"1109_CR37","doi-asserted-by":"crossref","first-page":"40640","DOI":"10.1074\/jbc.M407576200","volume":"279","author":"A Morinobu","year":"2004","unstructured":"Morinobu A, Kanno Y, O\u2019Shea JJ (2004) Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression. J Biol Chem 279:40640\u201340646","journal-title":"J Biol Chem"},{"key":"1109_CR38","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45","journal-title":"Nucleic Acids Res"},{"key":"1109_CR39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2007-06-093823","volume":"111","author":"J Yang","year":"2008","unstructured":"Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F et al (2008) Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 111:1610\u20131616","journal-title":"Blood"},{"key":"1109_CR40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1042\/bst0240692","volume":"24","author":"SM Sebti","year":"1996","unstructured":"Sebti SM, Hamilton AD (1996) Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Biochem Soc Trans 24:692\u2013699","journal-title":"Biochem Soc Trans"},{"key":"1109_CR41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.1996.tb52655.x","volume":"795","author":"J Magram","year":"1996","unstructured":"Magram J, Sfarra J, Connaughton S, Faherty D, Warrier R et al (1996) IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann NY Acad Sci 795:60\u201370","journal-title":"Ann NY Acad Sci"},{"key":"1109_CR42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4049\/jimmunol.165.1.10","volume":"165","author":"S Zhang","year":"2000","unstructured":"Zhang S, Lukacs NW, Lawless VA, Kunkel SL, Kaplan MH (2000) Cutting edge: differential expression of chemokines in Th1 and Th2 cells is dependent on Stat6 but not Stat4. J Immunol 165:10\u201314","journal-title":"J Immunol"},{"key":"1109_CR43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/eji.1830260519","volume":"26","author":"MC Mingari","year":"1996","unstructured":"Mingari MC, Maggi E, Cambiaggi A, Annunziato F, Schiavetti F et al (1996) Development in vitro of human CD4+ thymocytes into functionally mature Th2 cells. Exogenous interleukin-12 is required for priming thymocytes to produce both Th1 cytokines and interleukin-10. Eur J Immunol 26:1083\u20131087","journal-title":"Eur J Immunol"},{"key":"1109_CR44","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.4049\/jimmunol.163.11.5758","volume":"163","author":"JT Collins","year":"1999","unstructured":"Collins JT, Dunnick WA (1999) Cutting edge: IFN-gamma regulated germline transcripts are expressed from gamma2a transgenes independently of the heavy chain 3\u2032 enhancers. J Immunol 163:5758\u20135762","journal-title":"J Immunol"},{"key":"1109_CR45","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/eji.200535588","volume":"35","author":"CG Spilianakis","year":"2005","unstructured":"Spilianakis CG, Lee GR, Flavell RA (2005) Twisting the Th1\/Th2 immune response via the retinoid\u00a0\u00d7\u00a0receptor: lessons from a genetic approach. Eur J Immunol 35:3400\u20133404","journal-title":"Eur J Immunol"},{"key":"1109_CR46","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","volume":"110","author":"X Chen","year":"2007","unstructured":"Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R et al (2007) Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110:3804\u20133813","journal-title":"Blood"},{"key":"1109_CR47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.0804154","volume":"183","author":"JH Esensten","year":"2009","unstructured":"Esensten JH, Lee MR, Glimcher LH, Bluestone JA (2009) T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol 183:75\u201382","journal-title":"J Immunol"},{"key":"1109_CR48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.178.3.1341","volume":"178","author":"AR Gocke","year":"2007","unstructured":"Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC et al (2007) T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178:1341\u20131348","journal-title":"J Immunol"},{"key":"1109_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/imt.10.111","volume":"3","author":"N Ji","year":"2011","unstructured":"Ji N, Sosa RA, Forsthuber TG (2011) More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 3:435\u2013441","journal-title":"Immunotherapy"},{"key":"1109_CR50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.expneurol.2009.09.022","volume":"220","author":"R Liu","year":"2009","unstructured":"Liu R, Hao J, Dayao CS, Shi FD, Campagnolo DI (2009) T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol 220:366\u2013373","journal-title":"Exp Neurol"},{"key":"1109_CR51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-3083.2010.02425.x","volume":"72","author":"Y Shi","year":"2010","unstructured":"Shi Y, Wang H, Su Z, Chen J, Xue Y et al (2010) Differentiation imbalance of Th1\/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto\u2019s thyroiditis. Scand J Immunol 72:250\u2013255","journal-title":"Scand J Immunol"},{"key":"1109_CR52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/03009740903347983","volume":"39","author":"Y You","year":"2010","unstructured":"You Y, Zhao W, Chen S, Tan W, Dan Y et al (2010) Association of TBX21 gene haplotypes in a Chinese population with systemic lupus erythematosus. Scand J Rheumatol 39:254\u2013258","journal-title":"Scand J Rheumatol"},{"key":"1109_CR53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.immuni.2008.04.016","volume":"28","author":"M Shi","year":"2008","unstructured":"Shi M, Lin TH, Appell KC, Berg LJ (2008) Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28:763\u2013773","journal-title":"Immunity"},{"key":"1109_CR54","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","volume":"104","author":"JB Oliveira","year":"2007","unstructured":"Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K et al (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 104:8953\u20138958","journal-title":"Proc Natl Acad Sci USA"},{"key":"1109_CR55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.leu.2402832","volume":"17","author":"SC Bolick","year":"2003","unstructured":"Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J et al (2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17:451\u2013457","journal-title":"Leukemia"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1109-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1109-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:50:52Z","timestamp":1686390652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1109-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,9]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1109-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,9]]}}}